Emyria and UWA expand unique MDMA-inspired analogue library
Filed with ASX · · 2 pages · English
Story so far
Earlier from Emyria
- Emyria expands clinical sites for EMD-RX5 Phase 3 trial
- Emyria commences US preclinical program for MDMA library
- Appendix 4E and Annual Report
- Positive results received for Emyrias MDMA-inspired program
- Emyria receives ethics approval for EMD-RX5 Phase 3 trial
Later from Emyria
- Emyria completes $3m placement
- Placement completion and secondary trading notice
- Emyria accepted into National Institutes of Health Program
- Emyria receives $2.1M R&D tax incentive refund
- First dosing commenced for pivotal EMD-RX5 Phase 3 trial
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria